January 14, 2022
Rinvoq-Receives-New-Atopic-Dermatitis-Indication

Rinvoq Receives New Atopic Dermatitis Indication

January 14, 2022 – AbbVie's Rinvoq® (upadacitinib) has been approved to treat moderate to severe atopic dermatitis (AD) in patients at least 12 years old who have refractory disease